<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02482454</url>
  </required_header>
  <id_info>
    <org_study_id>chol001</org_study_id>
    <nct_id>NCT02482454</nct_id>
  </id_info>
  <brief_title>Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma</brief_title>
  <official_title>Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First People's Hospital of Changzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First People's Hospital of Changzhou</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether combining of radiofrequency ablation (RFA)
      and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with
      cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong
      survival of patients with cholangiocarcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2033</completion_date>
  <primary_completion_date type="Anticipated">July 2030</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adverse events related to RFA and CIK treatments.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>RFA alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients undergo radiofrequency ablation alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RFA+CIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous cytokine-induced killer cells were transfer via venous one week after RFA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>Radiofrequency ablation is performed percutaneously under CT/US guidance</description>
    <arm_group_label>RFA alone</arm_group_label>
    <arm_group_label>RFA+CIK</arm_group_label>
    <other_name>RFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cytokine-induced killer cells</intervention_name>
    <description>The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.</description>
    <arm_group_label>RFA+CIK</arm_group_label>
    <other_name>CIK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed cholangiocarcinoma

          -  Primary lesions (cholangiocarcinoma) are not resected

          -  Serum bilirubin level of 2.0 mg/dl or less.

          -  Performance status of 0 or 1.

          -  Expected survival of 1 year or more.

          -  Informed consent from the patient.

        Exclusion Criteria:

          -  With extrahepatic metastases

          -  With other neoplastic disease that is measurable or being treated other than
             cholangiocarcinoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changping Wu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The First People's Hospital of Changzhou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First People's Hospital of Changzhou</investigator_affiliation>
    <investigator_full_name>peng du</investigator_full_name>
    <investigator_title>Director of Science and Education Division</investigator_title>
  </responsible_party>
  <keyword>radiofrequency ablation</keyword>
  <keyword>cytokine-induced killer cells</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

